Duvelisib for treating relapsed and/or refractory peripheral T-cell lymphoma

Duvelisib is in development for relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), a group of lymphomas (cancer that begins in cells of the immune system), that develop from mature T-cells, which are a type of white blood cell. Relapsed means that the disease has reappeared after a period of remission; refractory is used to describe when the lymphoma does not respond to treatment. In the past, PTCLs have been treated with medicines used for B cell lymphomas, amore common type of blood cancer; but these medicines don’t work as well in PTCL. There is a need for new treatments with are proven to work in PTCL, which can control cancer growth and help people with PTCL to live longer.